CBA Launches Subsidiary Nonprofit Foundation 

Receives first grant for cerebral palsy and autism expanded-access study

Issued:  Nov. 13, 2017

The Cord Blood Association has announced the creation of a nonprofit foundation for scientific, educational and philanthropic projects. The foundation has received its first contribution, a grant from Viacord that will be used for studying therapies for cerebral palsy and autism.

The new subsidiary corporation, named the “Cord Blood Association Foundation,” has been a plan of CBA leaders since the founding of the association more than two years ago. The U.S. Internal Revenue Service recently granted 501(c)3 status to the foundation, exempting contributions from federal income tax. 

The initial project of the foundation will be a multi-center study that provides expanded access to autologous and related cord blood infusion for children with cerebral palsy and autism.

“We’re delighted to be the first organization to contribute to the work of the foundation,” Morey Kraus, PhD, Viacord chief science officer, said. “We understand that the grant will help support the collection of third-party data in an expanded-access study of autologous and sibling cord blood infusions in eligible children with cerebral palsy, autism spectrum disorder and related brain injuries.”

According to CBA President Joanne Kurtzberg, MD, the foundation’s planned expanded access multi-center clinical trial will treat children who have their own or a compatible sibling cord blood unit qualified and available for infusion. The medical center at Duke University will take the lead, and other treatment centers will be invited to participate.

Recently published clinical studies have suggested that cells contained in umbilical cord blood may be beneficial in treating neurological disorders including autism and cerebral palsy. The multi-center trial conducted through the CBA will allow for collection of additional clinical data to determine if these preliminary results can be confirmed in a larger group of patients with these disorders.